June 07, 2015 – The U.S. Food and Drug Administration (FDA) resently approved Sirolimus (Rapamune) to treat lymphangioleiomyomatosis (LAM), a rare, progressive lung disease that primarily affects women of childbearing age. This is the first drug approved to treat the disease. …

Sirolimus (Rapamune) for lymphangioleiomatosis (LAM), a very rare lung disease Read more »